Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine

Annals of the New York Academy of Sciences

Volumn 1222, Issue 1, 2011, Pages 14-18

  Goveia, Michelle G ^a   Ciarlet, Max ^a   Owen, Katey E ^a   Ranucci, Colette S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gastroenteritis; Pentavalent rotavirus vaccine; RotaTeq; Rotavirus

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HEALTH SURVEY; HUMAN; INFANT MORTALITY; LICENSING; ROTAVIRUS GASTROENTERITIS; SEROTYPE; VACCINATION; VACCINE PRODUCTION; VIRAL GASTROENTERITIS;

BOVINAE; HUMAN ROTAVIRUS A; ROTAVIRUS;

EID: 79952825906     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05970.x     Document Type: Article

References (38)

1. Parashar, U.D., A. Burton, C. Lanta, et al 2009. Global mortality associated with rotavirus disease among children in 2004. J. Infect. Dis. 200 (Suppl. 1): S9-S15.
2. Vesikari, T., P. Van Damme, C. Giaquinto, et al 2008. European society for paediatric infectious diseases/European society for paediatric gastroenterology, hepatology, and nutrition evidence-based recommendations for rotavirus vaccination in Europe. J. Pediatr. Gastroenterol. Nutr. 46: S38-S48.
3. Coffin, S.E., J. Elser, C. Marchant, et al 2006. Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. Pediatr. Infect. Dis. J. 25: 584-589.
4. Glass, R.I., U.D. Parashar, J.S. Bresee, et al 2006. Rotavirus vaccines: current prospects and future challenges. Lancet 368: 323-332.
5. American Academy of Pediatrics Committee on Infectious Diseases. 2009. Prevention of rotavirus-disease: updated guidelines for use of rotavirus vaccine. Pediatrics 123: 1412-1420.
6. Ciarlet, M & F. Schödel 2009. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 27(Suppl. 6): G72-G81.
7. Velázquez, F.R., D.O. Matson, J.J. Calva, et al 1996. Rotavirus infections in infants as protection against subsequent infections. N. Engl. J. Med. 335: 1022-1028.
8. Centers for Disease Control and Prevention (CDC). 1999. Withdrawal of rotavirus vaccine recommendation. MMWR. Morb. Mortal. Wkly. Rep. 48: 1007.
9. ®. Virology 403: 111-127.
10. Adams, W., K. Dezura, S. Diffenbach, et al 2003. Incubator design for optimal heat transfer and temperature control in plastic bioreactors. Pharm. Eng. 23.
11. Ranheim, T., P.K. Mathis, D.B. Joelsson, et al 2006. Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq). J. Virol. Methods 131: 193-201.
12. Clark, H.F., C.J. Burke, D.B. Volkin, et al 2003. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr. Infect. Dis. J. 22: 914-920.
13. Vesikari, T., D.O. Matson, P. Dennehy, et al 2006. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354: 23-33.
14. Vesikari, T., A. Karvonen, S. Ferrante, et al 2010. Sustained efficacy of pentavalent rotavirus vaccine, RotaTeq™, up to 3.1 years following the last dose of vaccine. Ped. Infect. Dis. J. 29: 957-63.
15. Food and Drug Administration. 2006. Product approval information-licensing action, package insert: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent), Merck. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research.
16. Centers for Disease Control and Prevention (CDC). 2009. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morb. Mortal. Wkly. Rep. 58(RR-2): 1-25.
17. World Health Organization. 2009. Rotavirus vaccination. Wkly. Epidmiological Rec. 84: 213-236.
18. Ciarlet, M., R. Sani-Grosso, G. Yuan, et al 2008. Safety and immunogenicity of concomitant use of the pentavalent rotavirus vaccine (RotaTeq™) and oral poliovirus vaccine (OPV). Pediatr. Infect. Dis. J. 27: 874-880.
19. Goveia, M.G., M.J. DiNubile, M.J. Dallas, et al 2008. REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr. Infect. Dis. J. 27: 656-658.
20. Goveia, M.G., Z.M. Rodriguez, M.J. Dallas, et al 2007. REST Study Team. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr. Infect. Dis. J. 26: 1099-1104.
21. Centers for Disease Control and Prevention (CDC). 2006. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morb. Mortal. Wkly. Rep. 55(RR-12): 1-13.
22. Centers for Disease Control and Prevention (CDC). 2009. Reduction in rotavirus after vaccine introduction-United States, 2000-2009. MMWR. Morb. Mortal. Wkly. Rep. 58: 1146-1149.
23. Centers for Disease Control and Prevention (CDC). 2008. Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. MMWR. Morb. Mortal. Wkly. Rep. 57: 697-700.
24. Tate, J.E., J.D. Mutuc, C.A. Panozzo, et al 2011. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr. Infect. Dis. J. 30: S30-S34.
25. Patel, M.M., D. Steele, J.R. Gentsch, et al 2011. Real-world impact of rotavirus vaccination. Pediatr. Infect. Dis. J. 30: S1-S5.
26. Wang F.T., T.C. Mast, R.J. Glass, et al 2010. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 125: e208-e213.
27. Boom, J.A., J.E. Tate, L.C. Sahni, et al 2010. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 125: e199-e207.
28. Payne, D.C., M.A. Staat, S. Donauer, et al Postlicensure effectiveness of RotaTeq™ vaccine in US children. Vaccines for enteric diseases. Spain, September 2009.
29. Tate, J.E., M.M. Patel, D. Steele, et al 2010. Global impact of rotavirus vaccines. Expert Rev. Vaccines 9: 395-407.
30. Belongia E.A., S.A. Irving, I.M. Shui, et al 2010. Vaccine Safety Datalink Investigation Group. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr. Infect. Dis. J. 29: 1-5.
31. ® in VAERS and VSD. Advisory Committee of Immunization Practices. Atlanta, October 2010. Accessed November 10, 2010.
32. th Annual Meeting of Infectious Disease Society of America. Philadelphia, USA. Oct-Nov 2009.
33. ®: progress towards developing world access. J. Infect. Dis. Suppl. 202 (Suppl. 1): S87-S92.
34. th Annual Meeting of the European Society for Pediatric Infectious Diseases. Nice, France, May 2010.
35. Patel, M., C. Pedreira, L.H. de Oliveira, et al 2009. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301: 2243-2251.
36. Armah, G., S.S. Samba, R.F. Breiman, et al 2010. Efficacy of the pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis in sub-Saharan Africa. Lancet 376: 606-614.
37. Zaman, K., D.D. Anh, J.C. Victor, et al 2010. Efficacy of the pentavalent rotavirus vaccine against severe rotavirus gastroenteritis among infants in developing countries in Asia: a randomized, double-blind, placebo-controlled trial. Lancet 376: 615-623
38. World Health Organization. 2009. Rotavirus vaccines: an update. Wkly. Epidmiological Rec. 84: 533-540.